Malignant pleural mesothelioma: A phase II trial with docetaxel

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 412-415

  Vorobiof, D A ^a   Rapoport, B L ^b   Chasen, M R ^c   Abratt, R P ^d   Cronje, N ^e   Fourie, L ^f   McMichael, G ^a   Hacking, D ^b  

^a Sandton Oncology Centre   (South Africa)

^b Medical Oncology Centre of Rosebank   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Bloemfontein Radiotherapy Practice   (South Africa)

^e Pretoria Oncology Practice   (South Africa)

^f Durban Oncology Centre   (South Africa)

Author keywords

Docetaxel; Malignant pleural mesothelioma; Phase II

Indexed keywords

CYTOTOXIC AGENT; DOCETAXEL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HALLUCINATION; HISTOLOGY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; CARCINOMA; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; MESOTHELIOMA; MIDDLE AGED; PLEURA TUMOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGE; PACLITAXEL; PLEURAL NEOPLASMS; SURVIVAL RATE; HUMANS; MIDDLE AGED; TAXOIDS;

EID: 0036018904     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf046     Document Type: Article

References (13)

1. Chemotherapy in malignant pleural mesothelioma. A review
2. Malignant pleural mesothelioma
3. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province
4. National Cancer Registry 1993-1995
5. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Co-operative Group
6. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer
7. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
8. Non parametric estimation from incomplete observations
9. Docetaxel for malignant mesothelioma. Phase II Study of the Eastern Co-operative Oncology Group (ECOG 2595)
10. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - A feasibility study
11. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B
12. Gemcitabine for malignant mesothelioma: A phase II trail by the Cancer and Leukemia Group B
13. The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma